Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma.

Charlott MörthAmal Abu SabaaEva FreyhultChristina ChristerssonJamileh HashemiNashmil HashemiMasood Kamali-MoghaddamDaniel MolinMartin HöglundAnna ErikssonGunilla Enblad

Published in: Cardio-oncology (London, England) (2021)

We observed a higher prevalence of CVD in DLBCL patients compared to controls prior to DXR therapy. Two proteins, SPON-1 and IL-1RT1, were related to pre-existing and emerging CVD in DXR treated patients. If confirmed in larger cohorts, IL-1RT1 may emerge as a reliable biomarker for unfolding CVD in DLBCL.

Keyphrases

diffuse large b cell lymphoma
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
epstein barr virus
peritoneal dialysis
stem cells
risk factors
patient reported outcomes
mesenchymal stem cells
bone marrow
cell therapy